Effects of an angiotensin II receptor antagonist, TCV-116, on insulin sensitivity in fructose-fed rats. 1994

K Shimamoto, and K Matsuda, and H Takizawa, and K Higashiura, and N Ura, and O Iimura
Second Department of Internal Medicine, School of Medicine, Sapporo Medical University, Japan.

This study was designed to examine the effects of an angiotensin II receptor antagonist on insulin sensitivity in an insulin-resistant hypertensive rat model (fructose-fed rats; FFR). Male Sprague-Dawley rats were fed a fructose-rich diet or standard chow for 4 weeks and then treated with either 1 mg/kg/day of TCV-116 (angiotensin II receptor antagonist) or vehicle for a further 2 weeks. Steady-state plasma glucose (SSPG) was measured while the animals were conscious. Insulin (2.5 mU/kg/min) and glucose (8 mg/kg/min) were simultaneously infused to determine insulin sensitivity in each group. The mean arterial pressure (MAP) was higher in the FFR (133 +/- 5 mmHg) than in the control group (120 +/- 3), and TCV-116 (110 +/- 4) decreased MAP significantly. SSPG was also higher in the FFR group (207 +/- 6 mg/dl) than in the control (137 +/- 10, p < 0.01), and TCV-116 (171 +/- 7) significantly reduced SSPG. The FFR group also had higher steady-state plasma insulin (SSPI) levels than the control (107 +/- 10 microU/ml for FFR and 63 +/- 12 for control, p < 0.05), and TCV-116 attenuated the increase in SSPI (73 +/- 11, p < 0.05). Thus, the angiotensin II receptor antagonist improved insulin resistance, as assessed by determining SSPG in FFR, suggesting that angiotensin II antagonism may play an important role in improving of insulin resistance in FFR.

UI MeSH Term Description Entries
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008297 Male Males
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005632 Fructose A monosaccharide in sweet fruits and honey that is soluble in water, alcohol, or ether. It is used as a preservative and an intravenous infusion in parenteral feeding. Levulose,Apir Levulosa,Fleboplast Levulosa,Levulosa,Levulosa Baxter,Levulosa Braun,Levulosa Grifols,Levulosa Ibys,Levulosa Ife,Levulosa Mein,Levulosado Bieffe Medit,Levulosado Braun,Levulosado Vitulia,Plast Apyr Levulosa Mein,Levulosa, Apir,Levulosa, Fleboplast
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000821 Animal Feed Foodstuff used especially for domestic and laboratory animals, or livestock. Fodder,Animal Feeds,Feed, Animal,Feeds, Animal,Fodders
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.

Related Publications

K Shimamoto, and K Matsuda, and H Takizawa, and K Higashiura, and N Ura, and O Iimura
January 1994, Blood pressure. Supplement,
K Shimamoto, and K Matsuda, and H Takizawa, and K Higashiura, and N Ura, and O Iimura
January 1994, Blood pressure. Supplement,
K Shimamoto, and K Matsuda, and H Takizawa, and K Higashiura, and N Ura, and O Iimura
January 1997, Fundamental and applied toxicology : official journal of the Society of Toxicology,
K Shimamoto, and K Matsuda, and H Takizawa, and K Higashiura, and N Ura, and O Iimura
March 2000, American journal of hypertension,
K Shimamoto, and K Matsuda, and H Takizawa, and K Higashiura, and N Ura, and O Iimura
July 2001, Diabetologia,
K Shimamoto, and K Matsuda, and H Takizawa, and K Higashiura, and N Ura, and O Iimura
November 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
K Shimamoto, and K Matsuda, and H Takizawa, and K Higashiura, and N Ura, and O Iimura
February 2002, Transplantation,
K Shimamoto, and K Matsuda, and H Takizawa, and K Higashiura, and N Ura, and O Iimura
March 1997, Japanese journal of pharmacology,
K Shimamoto, and K Matsuda, and H Takizawa, and K Higashiura, and N Ura, and O Iimura
December 1994, The American journal of physiology,
K Shimamoto, and K Matsuda, and H Takizawa, and K Higashiura, and N Ura, and O Iimura
January 1995, Hypertension (Dallas, Tex. : 1979),
Copied contents to your clipboard!